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Specific allergen immunotherapy (SIT) is disease-modifying and efficacious. However, the use of whole allergen preparations is
associated with frequent allergic adverse events during treatment. Many novel approaches are being designed to reduce the
allergenicity of immunotherapy preparations whilst maintaining immunogenicity. One approach is the use of short synthetic
peptides which representing dominant T cell epitopes of the allergen. Short peptides exhibit markedly reduced capacity to cross link
IgE and activate mast cells and basophils, due to lack of tertiary structure. Murine pre-clinical studies have established the feasibility
of this approach and clinical studies are currently in progress in both allergic and autoimmune diseases.
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S
pecific allergen immunotherapy (SIT) is disease
modifying and efficacious. However, the use of
whole-allergen preparations is associated with frequent
allergic adverse events during treatment. Many novel
approaches are being designed to reduce the allergenicity
of immunotherapy preparations while maintaining immu-
nogenicity. One approach is the use of short synthetic
peptides that represent dominant T-cell epitopes of the
allergen. Short peptides exhibit markedly reduced capacity
to cross-link immunoglobulin (Ig)E and activate mast cells
and basophils owing to a lack of tertiary structure. Murine
preclinical studies have established the feasibility of this
approach, and clinical studies are currently in progress in
both allergic and autoimmune diseases.
In non-allergic individuals, allergen exposure can be
associated with a failure to mount a detectable immune
response. In those individuals who do make an immune
response, it is characterized by non-inflammatory ‘‘reg-
ulatory’’ elements, such as interleukin (IL)-10-secreting T
cells.
1 The reasons why some individuals suffer from
allergic diseases and others do not despite equivalent
exposure are far from clear. Genetic and environmental
factors influence susceptibility. Analysis of genes associated
with allergic diseases suggests that susceptibility arises
from a complex interaction between multiple (frequently
polymorphic) genes.
2
A role for environmental factors in the pathogenesis of
allergic disease is demonstrated by the recent rise in the
prevalence of allergic sensitization and disease in indus-
trialized countries. Changes in sanitation, diet, vaccination
practices, and other facets of modern life have been linked
to increases in the prevalence of both allergic and
autoimmune disease, which probably arise as a result of
deficient immune regulation.
3
Several populations of cells with immunoregulatory
properties exist. They are important in homeostatic
regulation of inflammatory responses. A number of
populations of regulatory T cells have been characterized,
including ‘natural’ CD4
+CD25
+FoxP3
+ cells and additional
subsets of T helper (Th)3 cells producing transform-
ing growth factor (TGF) b and Tr1 regulatory cells
producing IL-10.
4 ‘‘Natural’’ regulatory T cells arise either
in the thymus or peripheral lymphoid organs, whereas
Th3 and Tr1 cells appear to arise from naive lymphocytes
in the periphery. Deficits in the functional activity of
CD4
+CD25
+ and Tr1 subsets of regulatory cells have
been reported in both allergic
5–8 and autoimmune
9–11
diseases.
SIT, through administration of allergen, is a form of
disease-modifying treatment that has been demonstrated
to be clinically efficacious in allergic rhinitis and asthma
and to provide enduring clinical benefit.
12–14 SIT reduces
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15 and
reduces the incidence of asthma in later life.
16,17
Mechanistic studies have shown down-regulation of Th2
responses in peripheral blood
18–20 and/or increased Th1
responses in the tissue.
19,21 SIT is also associated with the
induction of allergen-specific IgG to allergen.
22 An
increased Th1 to Th2 ratio accompanied by induction of
IgG initially suggested that efficacy was achieved through
the induction of a ‘‘protective’’ Th1 responses, which
antagonized Th2 allergen-specific responses. More
recently, an important role for IL-10 (and in some cases
TGF-b) has been identified. Bee keepers exposed to
multiple stings may develop local allergic reactions at the
beginning of the bee-keeping season, but these gradually
disappear over a period of days. Protection is associated
with strong allergen-specific T-cell IL-10 responses and
specific IgG4. IL-10 in combination with IL-4 drives IgG4
and provides a mechanistic link between T-cell and B-cell
responses.
23 Several studies have recently documented
increased numbers of cells expressing IL-10 (and in some
cases TGF-b) messenger ribonucleic acid (mRNA) or
protein in the peripheral blood
24–26 and tissues
27,28 of
treated individuals. Strategies are being developed to
induce regulatory cells in an antigen-specific fashion for
the treatment of allergic disease and perhaps, in the future,
autoimmune diseases.
Despite the efficacy of SIT, administration of whole-
allergen molecules carries the risk of adverse events, which
may be local or systemic and include life-threatening
anaphylaxis. Considerable resources have been invested in
developing strategies to reduce the allergenicity of
immunotherapy preparations while maintaining their
ability to modify T-cell and/or B-cell responses. One
approach is to treat patients with synthetic peptides
representing the immunodominant T-cell epitopes of the
allergen. Short peptides have the advantage of being unable
to cross-link allergen-specific IgE, leading to mast cell and
basophil activation (Figure 1).
Preclinical Experimental Models
Numerous murine models have been developed of both
allergic and autoimmune diseases that demonstrate the
efficacy of peptide immunotherapy. Prophylactic and
therapeutic protocols are effective. High-dose intravenous
administration of peptide in experimental autoimmune
encephalomyelitis (EAE), a model for multiple sclerosis,
resulted in clonal deletion of T cells and protection against
disease.
29 Intraperitoneal administration of peptides from
myelin basic protein (MBP) has also been shown to
prevent EAE.
30 MBP peptides administered intranasally to
T-cell receptor transgenic mice protected them from EAE
Figure 1. Comparison of whole-
allergen immunotherapy and pep-
tide immunotherapy. Whole-allergen
immunotherapy leads to the gene-
ration of both T helper 1 (Th1)
and T regulatory (Treg) responses.
Interleukin-10 (IL-10) and interferon-
c(IFN-c)pr od uc edb yTce l lsoftr ea te d
individuals reduce eosinophil recruit-
ment. IL-10, IFN-c, and IL-4 drive
production of allergen-specific immu-
noglobulin (Ig)G antibodies. Peptides
are presented to T cells with costimula-
tion leading to a mixed Th1-Treg
response. Whole-allergen molecules
can cross-link allergen-specific IgE on
the surface of mast cells and basophils,
leading to cellular activation and IgE-
mediated adverse events. APC 5 anti-
gen-presenting cell. In peptide immu-
notherapy, short peptides do not cross-
link allergen-specific IgE molecules and
thus mast cells and basophils are not
activated. Peptides are recognized by T
cells in the absence of costimulation,
resulting in a predominantly regulatory
response characterized by IL-10, which
decreases eosinophil recruitment and
mast cell activation.
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31 Similarly, in
arthritis models, peptides from type II collagen
32,33
protected animals from collagen-induced arthritis, whereas
peptides from the heat shock protein 60 protected mice
from adjuvant arthritis.
34 In diabetes models, peptides
from the insulin B chain,
35 glutamate decarboxylase
(GAD65),
36 and heat shock proteins
37 have been shown
to prevent the development of disease.
Peptide immunotherapy has also been evaluated in
models of allergic disease. Treatment of mice sensitized to
Fel d 1 with two long peptides resulted in decreased
production of IL-2 and allergen-specific IgG.
38 Curiously,
no allergy-related end points were evaluated. Intranasal
delivery of Der p 2 peptides to sensitized mice down-
regulated both T-cell and antibody responses to the native
protein.
39 In a model of birch pollen allergy, a dominant
T-cell epitope of Bet v 1 was used to treat sensitized mice
prophylactically and therapeutically following induction of
allergic inflammation.
40 Administration of peptides from
the bee venom allergen Api m4 or the hornet venom
allergen Dol m 5 to mice prior to sensitization with whole-
venom allergens caused a partial reduction in T-cell
proliferation and antibody production.
41 In separate
studies, mice were protected from anaphylaxis by treat-
ment with a mixture of three long peptides from Api m1.
42
Clinical Studies
Cat Allergen: Fel d 1
Several clinical studies of therapy with peptides from Fel
d 1 have been reported in the last decade (Table 1). In four
related studies, the safety and efficacy of a mixture of two
long (27 amino acids each) peptides were evaluated. In the
first of these, peptides were administered subcutaneously
to 95 cat-allergic subjects at weekly intervals at three doses
(7.5, 75, and 750 mg per injection).
43 At higher doses,
improvements in lung and nasal symptom scores were
observed. However, treatment was associated with fre-
quent adverse events occurring minutes to hours after
Table 1. Clinical studies of peptide immunotherapy in allergy.
Allergen
Peptide
Characteristics Study Design
Number of
Subjects
Route of
Administration Total Dose (mg) Clinical Outcomes Reference
Fel d 1 (cat) 2 3 27mer DBPC 95 SC 30–3,000 Nasal and lung
symptoms
43
2 3 27mer Open SC 150–4,500 Allergen PD20 46
2 3 27mer DBPC 42 SC 1,000 End-point titration,
skin LPR
47
2 3 27mer DBPC 133 SC 600–6,000 FEV1,* daily peak flow,
skin EPR, symptom
assessment
48
3 3 16/17mer Open 6 ID 80 Isolated LAR 44
12 3 16/17mer Open 8 ID 5 Isolated LAR and skin
LPR
49
12 3 16/17mer DBPC 24 ID 90 Skin LPR and EPR,
PC20,P D 20
50
11 3 16/17mer Open 8 ID 41.1 Skin LPR, PC20 51
12 3 16/17mer DBPC/open 28 ID 216–341 Nasal allergen
challenge, bronchial
challenge, skin LPR
53
Api m 1 (PLA2)
(bee)
1 3 11, 1 3 12, 1
3 18
Open 5 SC 397.1 Skin challenge PLA2,
bee sting
55
1 3 60, 1 3 53, 1
3 45
DBPC 16 SC 751.1 End-point skin
titration
58
4 3 18 Open-
controlled
24 ID 431.1 Skin LPR 57
DBPC 5 double-blind placebo controlled; EPR 5 early-phase reaction; FEV1 5 forced expiratory volume in 1 second; ID 5 intradermal; LAR 5 late
asthmatic reaction; LPR 5 late-phase reaction; PC20 5 provocative concentration of histamine that induces a 20% reduction in FEV1;P D 20 5 provocative
dose of inhaled allergen resulting in a 20% reduction in forced expiratory volume in 1 second; PLA2 5 phospholipase A2;S C5 subcutaneous.
*Only in subjects with reduced baseline FEV1 and only at one time point.
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be IgE mediated and may have arisen as a result of cross-
linking pre-existing peptide-specific IgE present in some
patients or through the development of de novo peptide-
specific IgE, as observed in others. The relatively large
peptides employed (27 amino acids) may have retained
conformational IgE epitopes or formed dimmers through
disulphide binding. Later adverse events included what
may have been isolated late asthmatic reactions, which
were later characterized in detail.
44 Related in vitro studies
showed reduced IL-4 production in peptide-specific T-cell
lines in vitro following therapy.
45
A further study evaluated allergen sensitivity by inhaled
challenge of allergic asthmatic subjects before and after
peptide therapy. Again, three dosage groups were used.
Treatment was also associated with reduced allergen PD20
(provocative dose of inhaled allergen resulting in a 20%
reduction in forced expiratory volume in 1 second [FEV1])
in the high-dose and medium-dose groups, together with
reduced allergen-induced IL-4 production from peripheral
blood mononuclear cells (PBMCs).
46
Not all studies demonstrate a positive clinical response.
Peptides or placebo was administered weekly by sub-
cutaneous injection (four doses of 250 mg) to 42 subjects
with cat-allergic rhinitis and/or asthma.
47 Treatment was
associated with frequent adverse events, mostly respiratory
in nature. PBMC cytokine secretion patterns were not
different in peptide-treated and placebo-treated subjects.
No changes in allergen-induced early- and late-phase skin
responses were observed.
In the largest of the four studies, 133 cat-allergic
subjects received eight subcutaneous injections of 750 mg
of the peptide mixture. The only significant clinical
outcome was observed in a secondary analysis as an
improvement in pulmonary function observed in indivi-
duals with reduced baseline FEV1; the improvement was
evident only at a single time point (3 weeks). Adverse
events were common as in the other related studies.
48
More recently, studies have been performed using
mixtures of shorter peptides from Fel d 1.
44,49–54 Peptides
were administered intradermally to cat-allergic asthmatic
subjects of mild to moderate disease severity. Treatment
with a single dose (5 mg of each peptide in a mixture)
resulted in significant reductions in the magnitude of the
cutaneous late-phase reaction to intradermal allergen
challenge. PBMC cultures stimulated with allergen in vitro
demonstrated reductions in both Th1 and Th2 cytokines.
49
Subsequently, in a double-blind, placebo-controlled
study, 24 cat-allergic asthmatic subjects were treated with
incremental, divided doses of peptides (total dose 90 mgo f
each peptide).
50 Treatment resulted in a significant
reduction in both early- and late-phase cutaneous reac-
tions to allergen challenge when compared with placebo.
Proliferative responses and Th1 and Th2 cytokine
production from PBMCs cultured with allergen were also
reduced in the active treatment group. Additionally, levels
of IL-10 production were increased. Peptide treatment
resulted in a significantly improved ability to tolerate
exposure to cats after therapy. No significant improve-
ments were observed in PD20 or PC20.
In a small open-label study using a similar peptide
preparation delivered at 2-week intervals rather than 3- to
4-day intervals, a significant improvement in PC20 was
observed.
51 Peptides were given by intradermal injection
with a 2-week interval and a lower total dose of peptide
was administered (41.1 mg of each peptide). The cutaneous
late-phase reaction was significantly reduced following
allergen challenge in the skin. Significantly more CD25
+
cells were found in allergen challenge skin sites from
peptide-treated subjects compared with placebo. The
number of CD4
+/IFN-c
+ cells also increased, suggesting
that recruitment of Th1 cells to the skin may play a role in
modifying the Th1:Th2 balance in the response to allergen.
No increases in IL-10
+ cells were observed in the skin, but
expression of TGF-b mRNA was increased.
Modulation of CD4
+CD25
+ regulatory T-cell function
has been evaluated in allergen-stimulated cultures in a
double-blind, placebo-controlled trial of peptide immu-
notherapy.
52 Proliferative responses and IL-13 production
from PBMCs cultured with allergen in vitro were signifi-
cantly reduced following peptide therapy as in previous
studies. However, no improvement in the suppressive
activity of CD4
+CD25
+ cells was observed. Thus,
CD4
+CD25
+ regulatory T cells may not play a significant
role in the mechanism of action of peptide immunotherapy.
The effect of peptide therapy on non-CD4
+CD25
+
regulatory T cells was also investigated. The induction of
allergen-specific ‘‘inducible’’ regulatory T cells was
addressed by mixing CD4
+ T cells with CD4
2 cells before
and after therapy.
54 The results demonstrated that CD4
+
cells isolated after therapy could suppress the proliferative
response of baseline CD4
2 cells. These data provide
evidence that peptide immunotherapy induces a popula-
tion of CD4
+ T cells with allergen-specific regulatory or
suppressive activity.
Insect Venom Allergy: Api m1
Fewer clinical studies have been reported with peptides
from the major bee venom allergen Api m1 (phospholipase
56 Allergy, Asthma, and Clinical Immunology, Volume 3, Number 2, 2007A2). In a small open study, five bee venom–allergic subjects
received subcutaneous incremental doses of a mixture of
three immunodominant peptides at weekly intervals.
55 The
cumulative peptide dose was 397.1 mg, with a first dose of
0.1 mg building to a final series of maintenance doses of
100 mg. One week after completion of peptide dosing,
subjects were challenged by subcutaneous administration
of 10 mg of whole Api m 1. All subjects tolerated Api m 1
challenge without systemic allergic symptoms. One week
later, a bee sting challenge was performed. Three
individuals tolerated the challenge without any allergic
sequelae; the remaining two subjects developed mild
systemic allergic reactions. Levels of allergen-specific
serum IgE or IgG4 did not change during the course of
peptide therapy. However, following subcutaneous chal-
lenge with Api m 1 1 week after the last peptide injection,
concentrations of both isotypes, in particular IgG4,
increased markedly.
Immunodominant T-cell epitopes have been defined by
direct peptide–major histocompatibility complex (MHC)
binding studies in Api m 1 by direct binding of peptides to
purified MHC class II molecules. Four dominant peptides
were identified; three of these represented similar regions
of the molecule to those employed previously.
56 These four
peptides were evaluated in a controlled, open-label, single-
blind study in subjects with mild bee venom allergy.
57
Treatment was well tolerated, with no allergic reactions
observed. Proliferation of T cells to purified allergen and
whole bee venom was significantly reduced after therapy.
Proliferative responses to treatment peptides were also
reduced. Th2 cytokine production following culture with
allergen was reduced but associated with a concomitant
increase in IL-10. Cutaneous late-phase reactions to
challenge with whole bee venom or Api m 1 were
significantly reduced. Allergen-specific IgG and IgE levels
were measured, revealing a significant, transient increase in
allergen-specific IgG and IgG4 following peptide immu-
notherapy.
RUSH desensitization was employed to treat bee
venom–allergic subjects using three synthetic polypeptides
spanning the whole Api m 1 molecule.
58 Patients received
approximately 250 mg of each peptide in incremental doses
at 30-minute intervals starting with 0.1 mg. Maintenance
injections of 100 mg (in some cases 300 mg) were given on
days 4, 7, 14, 42, and 70. T-cell proliferation increased
transiently during therapy in the active treatment group.
IFN-c and IL-10 levels but not Th2 cytokines increased.
Allergen-specific IgG4 but not IgE levels increased
throughout the study period. Peptide-specific IgE was
induced in some patients during the study. Skin sensitivity
to intradermal allergen challenge did not change signifi-
cantly. Peptide therapy was generally well tolerated.
However, local and disseminated erythema with occasional
hand palm pruritus was observed in two subjects at higher
doses.
In conclusion, peptide immunotherapy has been shown
to improve clinical outcomes and surrogate markers in a
variety of studies. Treatment appears to be associated with
the induction of IL-10 and a population of allergen-
specific regulatory or suppressor T cells. Numerous studies
in both allergic and autoimmune diseases support the
potential of this approach. However, significant issues still
need to be addressed, including whether delivery of T-cell
epitopes without competent B-cell epitopes will be
sufficient to provide efficacy equivalent to conventional,
whole-allergen immunotherapy. Short peptides (less than
20 amino acids) appear to have markedly reduced ability
to cross-link allergen-specific IgE and are less allergenic
than the whole molecule. However, delivery of high doses
of peptide may activate memory effector T cells, resulting
in T cell–mediated events such as isolated late asthmatic
reactions. Recent data suggest that such reactions can be
avoided with lower peptide doses, which are still capable of
inducing tolerance. Care must be taken in peptide
selection to ensure full population coverage based on the
MHC-binding characteristics of the peptides. In practice,
one peptide can contain several overlapping T-cell epitopes
with affinity for a range of MHC molecules. Further
clinical studies are required with preparations of short
peptides derived from the sequences of other allergens.
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